Anandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlate in gambling disorder

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Baenas, Isabel
• dc.contributor.author Solé Morata, Neus, 1988-
• dc.contributor.author Granero, Roser
• dc.contributor.author Fernández Aranda, Fernando
• dc.contributor.author Pujadas Bastardes, Mitona
• dc.contributor.author Mora-Maltas, Bernat
• dc.contributor.author Lucas, Ignacio
• dc.contributor.author Gómez-Peña, Mónica
• dc.contributor.author Moragas, Laura
• dc.contributor.author Pino-Gutiérrez, Amparo del
• dc.contributor.author Tapia-Martínez, Javier
• dc.contributor.author Torre Fornell, Rafael de la
• dc.contributor.author Potenza, Marc N.
• dc.contributor.author Jiménez Murcia, Susana
• dc.date.accessioned 2024-01-12T08:58:01Z
• dc.date.available 2024-01-12T08:58:01Z
• dc.date.issued 2023
• dc.description.abstract Introduction: Different components of the endocannabinoid (eCB) system such as their most well-known endogenous ligands, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), have been implicated in brain reward pathways. While shared neurobiological substrates have been described among addiction-related disorders, information regarding the role of this system in behavioral addictions such as gambling disorder (GD) is scarce. Aims: Fasting plasma concentrations of AEA and 2-AG were analyzed in individuals with GD at baseline, compared with healthy control subjects (HC). Through structural equation modeling, we evaluated associations between endocannabinoids and GD severity, exploring the potentially mediating role of clinical and neuropsychological variables. Methods: The sample included 166 adult outpatients with GD (95.8% male, mean age 39 years old) and 41 HC. Peripheral blood samples were collected after overnight fasting to assess AEA and 2-AG concentrations (ng/ml). Clinical (i.e., general psychopathology, emotion regulation, impulsivity, personality) and neuropsychological variables were evaluated through a semi-structured clinical interview and psychometric assessments. Results: Plasma AEA concentrations were higher in patients with GD compared with HC (p = .002), without differences in 2-AG. AEA and 2-AG concentrations were related to GD severity, with novelty-seeking mediating relationships. Conclusions: This study points to differences in fasting plasma concentrations of endocannabinoids between individuals with GD and HC. In the clinical group, the pathway defined by the association between the concentrations of endocannabinoids and novelty-seeking predicted GD severity. Although exploratory, these results could contribute to the identification of potential endophenotypic features that help optimize personalized approaches to prevent and treat GD.
• dc.description.sponsorship This research was supported by grants from the Delegación del Gobierno para el Plan Nacional sobre Drogas (2021I031), Plan Nacional sobre Drogas Convocatoria de subvenciones para proyectos de investigación financiados con fondos europeos 2022 (EXP2022/008847), Ministerio de Ciencia e Innovación (PDI2021-124887OB-I00 supported by MCIN/ AEI /10.13039/ 501100011033 and FEDER “Una manera de hacer Europa”), Instituto de Salud Carlos III (ISCIII) (FIS PI20/00132) and cofounded by FEDER funds/European Regional Development Fund (ERDF), a way to build Europe. CIBEROBN is an initiative of ISCIII. Additional funding was received by AGAUR-Generalitat de Catalunya (2021 SGR 00824 and 2021 SGR 00253) and European Union’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME/H2020, Prevention and Remediation of Insulin Multimorbidity in Europe) and no. 101080219 (eprObes). This study has also been funded by Instituto de Salud Carlos III through the grant CM21/00172 (I.B.) (cofunded by European Social Fund. ESF investing in your future). R.G. is supported by the Catalan Institution for Research and Advanced Studies (ICREA-Academia, 2021-Programme). I.L. is supported by the Ministerio de Ciencia e Innovación (MCIN), Agencia Estatal de Investigación (AEI), and by the European Union “NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (PRTR)” (Juan de la Cierva-Formación program, FJC2021–046494-I). M.N.P. was supported by the Connecticut Council on Problem Gambling. The funders had no role in the study design, data collection and analysis, decision to publish, or the preparation of the manuscript.
• dc.format.mimetype application/pdf
• dc.identifier.citation Baenas I, Solé-Morata N, Granero R, Fernández-Aranda F, Pujadas M, Mora-Maltas B, Lucas I, Gómez-Peña M, Moragas L, Del Pino-Gutiérrez A, Tapia-Martínez J, de la Torre R, Potenza MN, Jiménez-Murcia S. Anandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlate in gambling disorder. Eur Psychiatry. 2023 Nov 8;66(1):e97. DOI: 10.1192/j.eurpsy.2023.2460
• dc.identifier.doi http://dx.doi.org/10.1192/j.eurpsy.2023.2460
• dc.identifier.issn 0924-9338
• dc.identifier.uri http://hdl.handle.net/10230/58670
• dc.language.iso eng
• dc.publisher Cambridge University Press
• dc.relation.ispartof Eur Psychiatry. 2023 Nov 8;66(1):e97
• dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/847879
• dc.relation.projectID info:eu-repo/grantAgreement/ES/3PE/PDI2021-124887OB-I00
• dc.relation.projectID info:eu-repo/grantAgreement/ES/3PE/FJC2021-046494-I
• dc.rights © The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword 2-arachidonoylglycerol
• dc.subject.keyword Addictive behaviors
• dc.subject.keyword Anandamide
• dc.subject.keyword Gambling disorder
• dc.subject.keyword Impulsive behaviors
• dc.title Anandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlate in gambling disorder
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion